| INTRODUCTION
Bone homeostasis is believed to be maintained on the balance between formation and resorption mediated by osteoblasts and osteoclasts, respectively (Manolagas, 2000) . Reactive oxygen species (ROS) have been implicated as an important factor regulating the bone homeostasis. Several in vitro and in vivo studies reported that increased oxidative stress shows negative effects on bone formation by modulating differentiation and survival of osteoblasts (Bai et al., 2004; Jun et al., 2008; Lean et al., 2003; Mody, Parhami, Sarafian, & Demer, 2001) . Clinical studies have also showed that dysregulation of the antioxidant system and subsequent ROS accumulation are both important mediators of bone loss (Asagiri & Takayanagi, 2007) . However, it remains to be clarified how oxidative stresses induce bone loss.
Transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) plays a key role in the cytoprotection from oxidative stress and xenobiotic stress (Itoh et al., 1997; Suzuki, Motohashi, & Yamamoto, 2013) . Under unstressed conditions, Nrf2 protein level is maintained at low level as Nrf2 is ubiquitinated by Keap1 (Kelch-like ECH-associated protein 1)-based ubiquitin E3 ligase complex and degraded by the proteasome (Itoh et al., 1999; Kobayashi et al., 2004; Suzuki & Yamamoto, 2015) . Upon the exposure to oxidative and/or xenobiotic stresses that inactivates Keap1, Nrf2 is stabilized and activates transcription of various cytoprotective genes, conferring resistance against the stresses .
It has been reported that osteoclast differentiation is enhanced by Nrf2 deficiency (Hyeon, Lee, Yang, & Jeong, 2013) and suppressed by Nrf2 activation through deletion of Keap1 (Sakai et al., 2017) , suggesting that Nrf2 suppresses Keap1 is a negative regulator of Nrf2, a master transcription factor that regulates cytoprotection against oxidative and electrophilic stresses. Although several studies have suggested that the Keap1-Nrf2 system contributes to bone formation besides the maintenance of redox homeostasis, how Nrf2 hyperactivation by Keap1 deficiency affects the bone formation remains to be explored, as the Keap1-null mice are juvenile lethal. To overcome this problem, we used viable Keap1-deficient mice that we have generated by deleting the esophageal Nrf2 in Keap1-null mice (NEKO mice). We found that the NEKO mice exhibit small body size and low bone density.
Although nephrogenic diabetes insipidus has been observed in both the NEKO mice and renal-specific Keap1-deficient mice, the skeletal phenotypes are not recapitulated in the renal-specific Keap1-deficient mice, suggesting that the skeletal phenotype by Nrf2 hyperactivation is not related to the renal phenotype. Experiments with primary culture cells derived from Keap1-null mice showed that differentiation of both osteoclasts and osteoblasts was attenuated, showing that impaired differentiation of osteoblasts rather than osteoclasts is responsible for bone hypoplasia caused by Nrf2 hyperactivation. Thus, we propose that the appropriate control of Nrf2 activity by Keap1 is essential for maintaining bone homeostasis.
Communicated by: Hideyuki Saya bone resorption and subsequently promotes bone formation. In contrast, over-expression of Nrf2 negatively regulates osteoblastogenesis of MC3T3-E1 cells (Hinoi et al., 2006) . Although these observations suggest that differentiation of both osteoclasts and osteoblasts is suppressed by Nrf2 activation, physiological effects of the Nrf2 activation on bone development have not been fully clarified yet.
Nrf2 is constitutively activated in Keap1-null mouse (Wakabayashi et al., 2003) so that the Keap1-null mouse is a good model for the understanding of physiological contribution of Nrf2 activation to bone homeostasis. However, juvenile lethal due to hyperkeratosis in the upper digestive tract, which leads to the obstruction of the esophagus and death by starvation, made it infeasible to assess the effects of Keap1 deficiency on bone homeostasis (Wakabayashi et al., 2003) . In this study, therefore, we decided to use a viable mouse model harboring systemic activation of Nrf2, in which a squamous epithelium-specific Nrf2 deficiency in the context of systemic Keap1 deficiency (Keap1 -/-::Nrf2
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::K5-Cre or NEKO mice) corrects the hyperkeratosis of the esophagus, and subsequent lethality, while hyperactivation of Nrf2 is observed in most tissues, with the exception of the esophagus and skin . We found that NEKO mice exhibited small body size and low bone density. Experiments with primary cells derived from Keap1-null mice indicate that differentiation of both osteoclasts and osteoblasts is attenuated, indicating that Nrf2 activation inhibits differentiation of both osteoclasts and osteoblasts. These results support the notion that reduction in bone formation in NEKO mice is due to inhibition of osteoblast differentiation by Nrf2 activation and that Nrf2 activation leads to hypoplasia of bone mass by impairing differentiation of osteoblasts.
| RESULTS

| NEKO mice exhibit bone hypoplasia
To investigate function of Nrf2 on bone development, we examined Keap1-null mice in which Nrf2 is constitutively activated. Because of their juvenile lethality due to hyperkeratosis of esophagus (Wakabayashi et al., 2003) , it has been difficult to examine adult Keap1-null mice. We generated NEKO mice that are able to survive until adulthood. NEKO mice harbor hyperactivation of Nrf2 in most tissues with the exception of the esophagus and skin .
We first examined whole appearance of the mouse using X-ray photography (Figure 1a ,b). The picture showed that NEKO mouse was smaller than control mouse, but skeletal malformation was not observed in NEKO mice (Figure 1a density (vBMD., Figure 2f ) and cortical bone tissue mineral density (CB. TMD., Figure 2g ) in NEKO mice is observed. The decrease in bone mass was reproducibly observed even in elder NEKO mice ( Figure S1a-c) . Showing very good agreement with the result of femur, three-dimensional reconstruction image of cranial bone displays that the radiolucency is increased in NEKO mice compared to control mice ( Figure S2a-d) , whereas no malformation in NEKO mice is observed ( Figure S2a-d) . Although intensity of Alcian bluepositive cartilage in growth plate tends to be decreased in NEKO mice ( Figure S3 ), thickness of femur growth plate was not affected in the mice, suggesting that chondrogenesis is also mildly affected by Keap1 deficiency. In addition, blood ionized calcium level of NEKO mice was lower than that of control mice (Figure 2h ), indicating that the severe bone hypoplasia leads to reduction in blood ionized calcium level in NEKO mice. These results show that hyperactivation of Nrf2 leads to severe bone hypoplasia in mouse.
| Bone hypoplasia of NEKO mice is not linked to their renal failure
Because NEKO mice display nephrogenic diabetes insipidus , we tested whether bone hypoplasia of Flox ::Pax8-rtTA::tetO-Cre, or Keap1 TKO mice) and treated the mice with DOX from the embryonic stage, by administration of DOX to the pregnant mother. The Keap1 gene was specifically deleted in the renal tubular cells, and the Keap1 TKO mice display nephrogenic diabetes insipidus, like NEKO mice . Femur length of Keap1 TKO mice is comparable to that of control mice (Figure S3a,b) . X-ray photography and three-dimensional reconstruction imaging show no different appearance between Keap1 TKO and control mice ( Figures S3c,d and S4a-d). In addition, there is no difference of bone morphometric parameters and blood ionized calcium level between Keap1 TKO and control mice ( Figure  S4e-h) , demonstrating that the severe bone hypoplasia in NEKO mice is not attributable to their renal dysfunction.
| Nrf2 hyperactivation leads to perturbation of bone homeostasis
We next investigated how Keap1 deficiency affects the differentiation of osteoblasts and osteoclasts. First, we conducted in vitro differentiation experiments of osteoclasts using bone marrow (BM)-derived cells from NEKO and control mice. The BM cells were cultured in the medium supplemented with M-CSF and RANKL (Figure 3a) . After two-day preculture with M-CSF, RANKL was added to induce osteoclast differentiation. Five days after the induction, mature differentiated osteoclasts were visualized by TRAP staining. Whereas control BM cells produced the largest number of TRAP-positive multinucleated mature osteoclasts (Figure 3b ), NEKO mouse-derived BM cells produced fewer or practically no osteoclasts (Figure 3c ). This showed very good agreement with the previous report that osteoclast differentiation of splenic cells from Keap1-deficient mice was impaired (Sakai et al., 2017) . These results indicate that Nrf2 activation suppresses osteoclast differentiation.
Because NEKO mice showed severe bone hypoplasia despite the diminished osteoclast production from BM cells, we surmised that osteoblast differentiation might also be impaired in NEKO mice. To address this hypothesis, we conducted in vitro osteoblast differentiation experiment using newborn calvarias of Keap1 +/-and Keap1 -/-mice. Collected cells were precultured for 2 days and induced to differentiate to osteoblasts by adding ascorbic acid, dexamethasone and β-glycerophosphate (Figure 3d ). Osteoblast differentiation was examined by measuring alkaline phosphatase (AP) staining. While the osteoblast differentiation of cells from Keap1 +/-mice was nicely observed, that of Keap1 -/-mice were severely impaired ( Figure 3e ). Taken together, these results thus indicate that Nrf2 suppresses osteoblast differentiation and that reduction in bone mass in NEKO mice is due to impaired bone homeostasis by decreased osteoblast differentiation.
| DISCUSSION
It has been shown that the Keap1-deficient mouse is a useful model for the study of Nrf2 hyperactivation, and the juvenile lethality of mice hampers uses of the mice (Wakabayashi et al., 2003) . To overcome this difficulty, we recently generated alive model of Keap1-null mouse referred to as NEKO mouse . In this study, we examined pathophysiological contribution of Nrf2 activation to bone formation using the NEKO mice. We found that hyperactivation of Nrf2 leads to low bone density. This novel phenotype of Nrf2 activation is independent of nephrogenic diabetes insipidus identified in NEKO mice in the previous study . Primary culture experiments using newborn calvarias cells from Keap1-null mice indicate that impaired osteoblast differentiation is responsible for bone hypoplasia caused by the Nrf2 hyperactivation. These results indicate that the Nrf2 hyperactivation leads to bone hypoplasia. The finding that osteoblast differentiation of primary newborn calvarias cells is impaired by the Keap1 deficiency is consistent with the previous observation that Nrf2 overexpression in osteoblastic MC3T3 cells showed osteoblast differentiation defects (Hinoi et al., 2006) . Nrf2 has been reported to interact with Runx2, a master transcription factor of osteoblastogenesis, and interferes with the Runx2-dependent transcriptional activation (Hinoi et al., 2006) . Although Nrf2 in general acts as an activator (Katoh et al., 2001; Sekine, Hirata, Mine, & Fukano, 2016) , in certain context Nrf2 acts as a suppressor of gene expression, for instance, genes for inflammatory cytokines (Kobayashi et al., 2016) . Therefore, the repressor function of Nrf2 for Runx2 gene could be a plausible mechanism underlying the impaired osteoblastogenesis by Nrf2. Another report showed that some members of leucine zipper (bZIP) transcriptional factors, such as C/ EBPβ and ATF4, are involved in osteoblastogenesis (He et al., 2001) , implying that Nrf2 might compete with the other bZIP members for their binding sequence. Moreover, a recent report shows that Nrf2 activation impairs quiescence and bone marrow reconstitution capacity of hematopoietic stem cells (Murakami et al., 2017) , implying that supply of osteoblasts may be impaired by the Nrf2 activation. Regarding molecular mechanism of Nrf2-mediated suppression of osteoclastogenesis, we recently found that Keap1-deficient macrophages are unable to differentiate into osteoclasts in vitro via attenuation of RANKL-mediated signaling and expression of NFATc1 (nuclear factor of activated T-cell cytoplasmic 1) (Sakai et al., 2017) .
In light of the use of Nrf2-inducing compounds as potential medical treatments, many studies have shown that pharmacological Nrf2 induction gives rise to a protective effect against a variety stresses, including ischemia-reperfusion injury (Nezu et al., 2017) , carcinogenesis (Kensler & Wakabayashi, 2010) and inflammation (Keleku-Lukwete, Kobayashi et al., 2016) . Although there are many papers that have assessed effects of Nrf2-inducing chemicals (Kensler et al., 2013; , to our knowledge it has never been verified that such Nrf2 inducers provoke impairment of bone homeostasis. In this regard, we previous found that Nrf2 induction during development causes nephrogenic diabetes insipidus , but the Nrf2 induction during adulthood will not cause such adverse effects in the kidney. These observations suggest that the Nrf2-inducer treatment may have a critical period during development. Further investigations are necessary to clarify whether Nrf2 is actually induced in bone cells under physiological or pathological condition.
Of note, de novo mutations in human NRF2 gene that induce NRF2 were recently identified (Huppke et al., 2017) , and the cases with the NRF2 induction displayed mild developmental delay, short stature and delayed bone age (Huppke et al., 2017) . The phenotypes observed in the cases are consistent with the phenotype we have observed in the NEKO mice, including the small body length and low bone density. These observations in human cases and in NEKO mouse analysis in combination support the contention that the Nrf2 hyperactivation in certain developmental window leads to the impairment of bone formation and homeostasis. 
| Osteoblast differentiation culture
For in vitro osteoblast differentiation, newborn calvarias were digested with 1 mg/ml collagenase (Wako) and 2 mg/ml dispase (Gibco) at 37°C for 15 min with the repeat of this at least 5 times. The cells were then cultured with α-MEM (Wako) with 10% FBS for 5-7 days. After primary culture cells were treated with 0.25% Trypsin-EDTA solution (Sigma), cells were cultured in osteogenic medium (50-μM ascorbic acid, 10-nM dexamethasone and 10-mM β-glycerophosphate) for 14 days. For quantifying alkaline phosphatase (ALP) activity, ALP assay was performed as described (Nishikawa et al., 2010) . For quantitative analysis, the densities of scanned images of stained plate were measured using ImageJ software.
| Osteoclast differentiation culture
The in vitro osteoclast differentiation was conducted as described (Nishikawa et al., 2010) . Briefly, bone marrow cells were flushed out from femur and tibia of female mice in each genotype at 7-10 weeks. The cells were cultured in 10% FBS-αMEM with 10 ng/ml of M-CSF (R&D Systems) for 2 days, and osteoclast precursor cells were obtained. The cells were cultured in 10% FBS-αMEM with 50-ng/ml RANKL (Oriental Yeast) in the presence of 10-ng/ml M-CSF for additional 5 days. Quantification of tartrate-resistant acid phosphatase (TRAP) activity was performed by TRACP & ALP doublestain Kit (Takara). To evaluate osteoclast differentiation, TRAP-positive multinucleated cells were counted as mature osteoclasts. For quantitative analysis, the densities of scanned images of stained plate were measured using ImageJ software.
| Microcomputed tomography analysis
Whole body or full length of femur of several stage female mice was μCT scanned with a Latheta to analyze bone shape, lipid volume and bone morphometry. Three-dimensional reconstruction images of bone were obtained by Amira (M@xnet).
| Alcian blue staining
Femurs were fixed in 70% ethanol, decalcified paraffinembedded and sectioned to stain with Alcian blue. For quantitative analysis, the densities and thickness of scanned images were measured using ImageJ software.
| Statistical analyses
Data are expressed as the mean ± SE. For statistical analysis, pairwise comparisons were made by Mann-Whitney U test. p-values < .05 were considered statistically significant.
